Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Expansion Therapeutics

Request full access

A drug discovery and development company pursuing the vast potential of small molecule medicines for RNA-mediated diseases

Jupiter, United StatesFounded 2016Biotech & Life Sciences

About Expansion Therapeutics

Expansion Therapeutics, Inc., established in 2016, is a biopharmaceutical company focused on developing orally available, small molecule medicines for severe RNA-mediated diseases. The company was founded by Matthew D. Disney, Ph.D., a professor of chemistry at The Scripps Research Institute, whose laboratory developed the underlying technology. His extensive research into RNA-modifying compounds and the creation of a computational platform to identify druggable RNAs laid the groundwork for the company's scientific approach. This background directly informs the company's mission to create therapies for diseases that currently have no cure. Expansion Therapeutics operates in the biopharmaceutical market, specifically targeting a class of disorders known as expansion repeat disorders, which includes conditions like myotonic dystrophy type 1 (DM1), frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), and various ataxias. The company's business model is centered on the research and development of a pipeline of proprietary drug candidates. Its primary asset is a platform that enables the design of small molecules capable of binding to RNA structures, a historically challenging target for drug development. By creating oral therapies, the company aims to offer more accessible and convenient treatment options compared to other modalities. The ultimate goal is to move these candidates through clinical trials and eventually commercialize them, generating revenue through drug sales and potential licensing partnerships with larger pharmaceutical firms. To date, Expansion Therapeutics has secured significant financial backing to advance its research. The company raised $55.3 million in a Series A financing round and later completed an $80 million Series B financing round in 2021, with participants including Cormorant Asset Management, RA Capital Management, and Novartis Venture Fund, among others. This capital is being deployed to progress its portfolio of RNA-targeted small molecules for multiple neurological diseases into clinical development.

Source: Dealroom company data

At a glance

Status
Operational
Employees
16
Open positions
None listed
Dealroom signal
61.4/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Genetics and genomics, Spinout, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES BOther financing Sep 2021 $80M $320M Kleiner Perkins · 5AM Ventures · Cormorant Asset Management · RA Capital Management —
SERIES AOther financing Jan 2018 $55M $221M Alexandria Venture Investments · RA Capital Management · Sanofi-Genzyme BioVentures · Novartis Venture Fund —
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Expansion Therapeutics website traffic

Latest recorded traffic for Expansion Therapeutics is 580 monthly website visits, down 58.6% over the last three months. Expansion Therapeutics's team grew 0% over the past year.

Latest monthly visits580 3-month web change-58.6% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Expansion Therapeutics in the Jupiter ecosystem

Live from Dealroom

The Expansion Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

12 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A11 investors entered at this stage

Other known investors1 additional known investor

  • Scripps Translational Science Institute
Team profiled 11 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Jupiter HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Expansion Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Expansion Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.